In brief
Recent trials have unveiled a mango-flavoured pill designed to effectively combat intestinal worms, a troubling parasitic infection affecting around 1.5 billion individuals globally. This innovative treatment merges two established anti-parasitic medications, demonstrating enhanced efficacy in eliminating these harmful worms, particularly in children. Such infections are often acquired through contaminated food or water, leading to debilitating gastrointestinal symptoms, malnutrition, and anemia.
Known as soil-transmitted helminths (STHs), these parasites, including whipworm and hookworm, pose a significant health risk in many developing regions where sanitation and hygiene are inadequate. The newly developed pill represents a significant advancement, offering a straightforward solution for mass treatment campaigns which are vital for regions striving to meet World Health Organization targets for parasitic disease elimination.Led by Prof. Jose Muñoz, researchers from eight European and African institutions are excited about the pill's potential benefits. The treatment can be given as either a single dose or in a short course covering three days, facilitating broad distribution and administration. Importantly, combining two drugs may help curtail the risk of parasites developing resistance to treatment, which is an ongoing challenge with current medications.A recent clinical trial conducted on 1,001 children aged 5-18 from Ethiopia, Kenya, and Mozambique indicated that this approach could be a breakthrough in managing diverse infections. While initial findings are promising, experts like Prof. Hany Elsheikha from the University of Nottingham acknowledge some limitations, noting that the results may vary among different age groups and geographic regions.The successful results of the study are now under review by European and African regulatory bodies, with outcomes anticipated in early 2025. Meanwhile, additional trials involving 20,000 participants are being organized in Kenya and Ghana to further evaluate the pill's efficacy. As Dr. Stella Kepha from Kenya Medical Research Institute reinforces, the potential for this treatment to enhance health in impacted communities is substantial, though more research is needed to ensure successful implementation.


